Aims: Liver transplantation is the only curative treatment available for patients with end-stage alcoholic liver disease. As different studies showed a significant association between leptin plasma levels, gene methylation patterns and the extent of craving in alcohol-dependent patients, we investigated the effect of liver transplantation on leptin expression and promoter methylation. Short Summary: The present study shows that in alcohol-dependent patients with liver cirrhosis leptin is significantly higher before liver transplantation and decreases significantly after transplantation. Alcohol-dependent patients on the waiting list had significantly higher leptin promoter methylation values than patients who underwent liver transplantation for other reasons than alcoholic liver disease. Methods: Only plasma of 118 and peripheral blood mononuclear cells of 121 patients were used: healthy controls (C, n = 24/22), alcohol-dependent patients without ethyltoxic liver cirrhosis (AD, n = 24/22), patients after liver transplantation for other reasons than ethyltoxic liver cirrhosis (C-Tx, n = 18/21), alcohol-dependent patients suffering from ethyltoxic liver cirrhosis on the transplantation waiting list (Pre-Tx, n = 30/28) and patients with prior ethyltoxic liver cirrhosis after liver transplantation (Post-Tx, n = 22/28). Results: Leptin protein was significantly elevated in the pre-transplantation cohort when compared to post-transplantation and alcohol-dependent cohorts. Furthermore, leptin promoter methylation was higher in ethyltoxic patients before transplantation compared to non-ethyltoxic patients after transplantation, but not when compared to ethyltoxic patients after transplantation. C-Tx had lower methylation values than all other groups except for Post-Tx.
INTRODUCTION
Liver transplantation (LTX) is the only curative treatment available for patients with end-stage alcoholic liver disease (ALD). Between 1999 and 2009, 20% of all indications for LTX in Europe were drawn because of ALD (Adam et al., 2012) . In this sample, 13% of liver cirrhosis (LC) were associated with hepatitis C, which can now be effectively treated in more than 90% of cases (Manns et al., 2017) . ALD is expected to become even more important for clinicians and researchers concerned with LTX in the years to come. As Addolorato et al. (2016) pointed out, 90-95% of patients suffering from ALD are never evaluated for LTX (Addolorato et al., 2016) even though ALD represents the leading cause of LC in both Europe and the USA (Heidelbaugh and Bruderly, 2006; Tilg and Day, 2007) . When it comes to LTX, alcohol-dependent (AD) patients frequently relapse to alcohol consumption after transplantation (approximately 10-46%) (Ursic-Bedoya et al., 2015) which presents one potential reason amongst others why some controversial stigmata towards AD LTX recipients exist-meaning that because of the nature of the disease some people think that LTX should be restricted in ALD (Neuberger, 2007; Gramenzi et al., 2011) . Research about causes and outcomes of LTX in Europe in which 95% of all cases were included showed that improvement in surgical results also depends on improved patient selection (Adam et al., 2012) . In this selection process, psychiatric evaluation of the patient suffering from AD could prove essential for the choice of treatment of LTX patients after the procedure.
To this end, it is essential to understand the mechanisms leading to alcohol craving-one of the main reasons for relapse and thereby a possible risk to the patient's health and survival after LTX. In a recent review, the authors identified the time of abstinence <6 months before LTX as one of the major reasons for relapse (Lim et al., 2017) . They also mentioned the existence of conflicting evidence, suggesting that it is not a reliable indicator and that it needs to be examined further (Lim et al., 2017) . When it comes to craving in association with abstinence time, some evidence shows that for alcohol addiction an incubation of craving is present over abstinence periods. Li et al. (2015) concluded that the highest craving during an abstinence period was after 60 days when compared to other time points. Hence it is crucial to look at craving before LTX and parameters that are associated with craving.
Leptin is a peptide which is mainly secreted by adipocytes and plays a crucial role in appetite regulation in the hypothalamus (Inui, 1999; Kraus et al., 2001; Hillemacher et al., 2007) . Several studies have exhibited a relationship between craving and leptin (Kiefer et al., 2001a; Hillemacher et al., 2007 Hillemacher et al., , 2015 Lenz et al., 2010) , and its influence on the hypothalamus-pituitary-adrenocortical (HPA) axis in the hypothalamus, where it alters the gene expression of corticotropin-releasing-hormone (CRH) and proopiomelanocortin (POMC), two hormones that regulate the HPA-axis (Inui, 1999; Kiefer et al., 2001a) . Furthermore, leptin levels are elevated in alcoholic cirrhosis independently of body mass index (BMI) (McCullough et al., 1998; Bolukbas et al., 2004) . Recent research showed that increased leptin can lead to a reduced dopaminergic action in the mesolimbic system, which can lead to higher craving and thus influence the addictive behavior (Aguiar-Nemer et al., 2013) . Moreover, Kiefer et al. (2005) have shown that increased leptin levels during abstinence indicate a risk for relapse. In this sense, recent research indicates that leptin may serve as a useful marker of risk for relapse among abstinent alcohol-dependent patients (Aguiar-Nemer et al., 2013) and thus might be of relevance in the evaluation of LTX patients before transplantation.
In addiction research, changes in epigenetic mechanisms-mainly in DNA methylation-have been the focus of several studies. In DNA methylation, DNA methyltransferase adds methyl groups to the 5′ position of the cytosine pyrimidine ring (Hillemacher et al., 2015) . Cytosine-phosphatidyl-guanine (CpG) dinucleotides are the primary region where such methylations are found (Hillemacher et al., 2015) . The expression of a particular gene is typically downregulated through methylation. In recent years, evidence of changes in gene methylation in the context of alcohol addiction has been found and discussed for atrial natriuretic peptide (Glahn et al., 2014) , vasopressin (Glahn et al., 2014) , dopamine transporters (Hillemacher et al., 2009) , POMC (Muschler et al., 2010) , NMDA 2B receptor (Bonsch et al., 2005; Biermann et al., 2009) , alphasynuclein (Bonsch et al., 2005) , ALDH2 (Pathak et al., 2017) and BDNF (Heberlein et al., 2017) , to name a few. For leptin promoter methylation patterns, we observed that low methylation status is associated with increased serum leptin levels and elevation in craving (Hillemacher et al., 2015) .
Before LTX, leptin expression is upregulated due to the inhibited liver function, thereby leading to a vicious cycle due to its role in increasing steatosis and fibrosis in the liver (McCullough et al., 1998) . Hence, we hypothesize that after LTX-because of the normalized liver function-leptin expression would decrease to a physiological level. Moreover, a relation between leptin serum levels and the response to pharmacological treatment has been described (Kiefer et al., 2001a,b) . Looking at the pathogenesis of ALD, ethyltoxic LC (ELC) is associated with increased levels of leptin when compared to healthy controls (McCullough et al., 1998; Bolukbas et al., 2004) .
In this pilot study, we aim to investigate differences in leptin expression and leptin promoter methylation in AD patients with end-stage LC before and after LTX. Based on our previous studies and the relationship between leptin and liver fibrosis, steatosis and ELC (McCullough et al., 1998; Bolukbas et al., 2004) , we hypothesize that leptin expression is higher before LTX in comparison to healthy controls and AD patients and lower in the patients who had an LTX. For the methylation analysis, we assumed that before LTX the lowest mean methylation of the promoter region would be present and that after transplantation the levels would be comparable to healthy individuals. Keeping in mind the relationship between craving and leptin (Kiefer et al., 2001a; Hillemacher et al., 2007 Hillemacher et al., , 2015 Lenz et al., 2010) , and the possible role of leptin serving as a biomarker for relapse, this study has the aim to analyze possible changes in leptin in patients with ethyltoxic cirrhosis.
METHODS AND MATERIALS

Subjects
The present investigation was done as part of a pilot project on neurobiological mechanisms in ALD funded by the IFB-Tx (Integrated Research and Treatment Center Transplantation). Our study was approved by the local Ethics Committee of the Hanover Medical School (authorization number: 3322-2016). We conducted this investigation by the Declaration of Helsinki. Written informed consent was given by every patient/control who participated in this study. The AD patients were recruited in the Department of Psychiatry, Social Psychiatry and Psychotherapy of Hanover Medical School, while all LTX patients were collected in the Department of Gastroenterology, Hepatology, and Endocrinology, Hanover Medical School.
For the leptin protein measurement, we used only plasma gathered from 118 human subjects. The sample consisted of healthy controls (C, n = 24), AD patients without LC (AD, n = 24), patients who had an LTX for other reasons than ELC (C-Tx, n = 18), e.g. hepatitis B or C, patients suffering from ELC and who were on the LTX waiting list (Pre-Tx, n = 30) and patients with ELC who previously had an LTX (Post-Tx, n = 22). The mean age was 52.08 (SD = 4.10) for C, 55.79 (SD = 7.15) for AD, 46.06 (SD = 13.00) for C-Tx, 53.60 (SD = 9.35) for Pre-Tx and 55.55 (SD = 7.56) for Post-Tx groups (see Table 1 ). For the methylation analysis, we gathered 129 samples (peripheral blood mononuclear cells (PBMC)) of which we analyzed 121 as we had to exclude eight measurements after quality assessment. The sample consisted of: C (n = 22, average age = 52.41, SD = 4.10), AD (n = 22, average age = 56.82, SD = 6.49), C-Tx (n = 21, average age = 44.52, SD = 14.49), PreTx (n = 28, average age = 52.96, SD = 8.63) and Post-Tx (n = 28, average age = 54.71, SD = 8.25) (see Table 1 ). Age defines the time interval between birth and the day of sample collection, not the date of analysis, due to the broad time span in which the probes were collected. In both sample collections, age was significantly lower in the control group when compared to the AD group according to the t-test for independent samples. Age in the C-Tx group was significantly lower than the mean age in all other groups except for the leptin expression control group (see Table 1 ). Regarding other factors associated with leptin expression, such as nicotine consumption (Potretzke et al., 2014) , we were not able to gather any information from the cirrhotic patients due to the retrospective character of this study. The same holds true for Alcohol Use Disorders Identification Test (AUDIT) scores and BMI at the point in time when the blood was drawn. Our inability to present meaningful information on this data bears several limitations (see Discussion).
Exclusion criteria in the AD and control group were LC independent of its pathogenesis and comorbid diseases or disorders that do not allow the patient to give written consent (such as florid schizophrenia, acute suicidality or florid manic depression). Inclusion criteria in the C and AD group were age above 45 and for the AD group the definite diagnosis of alcohol dependency (ICD 10 F10.1) or harmful use (ICD 10 F10.2). We decided to include mostly patients above age 45 because the mean age for the transplantation groups (C-Tx, Pre-Tx and Post-Tx) is between 44 and 55 years (see Table 1 ). As leptin expression also depends on age, we thereby attempting to minimize possible effects of age on leptin expression.
All AD patients were selected over the course of their psychiatric treatment and showed all markers of alcohol addiction, such as psychometry (e.g. AUDIT score), liver values, etc. We only included those patients who were not in alcohol withdrawal delirium. Patients with alcoholic fatty liver disease were included as long as no severe steatohepatitis or LC were present. To ensure this, we assessed the patients' alanine transaminase and international normalized ratio values over the course of their treatment. If the values normalized throughout the treatment with the beginning of alcohol abstinence, the patients were included in the study.
All healthy controls gave written informed consent and were asked about their drinking behavior as well as the existence of liver diseases. If they did not display evidence of current alcohol abuse and reported no concurrent liver disease they were included in the study. We collected full blood samples of all patients which were immediately processed into plasma and PBMCs and both frozen at −80C°. For newly acquired samples, we collected fasted morning blood. For PBMCs accessed in cooperation with the gastroenterology department, information about point in time and feeding status of patients were not available. To further characterize the Demographics of the groups with respect to the blood samples used for further analysis. C = healthy controls; C-Tx = non-AD patients after LTX; MELD = Model of End Stage Liver Disease; N = number, Pre-Tx = AD patients before transplantation; Post-Tx = AD patients after transplantation; SD = standard deviation; Tx = transplantation. X/N = actual number of samples for which we had the MELD score out of the total number of samples per group, + = for one control we did not know the exact birthday but the birth year which we then used for the age calculation. Age differences were calculated with the t-test for independent samples. The alpha level was set at 0.05. All values are rounded up to two decimal digits.
cirrhotic patients, we collected MELD (model of end-stage liver disease) scores (see Table 1 ). As values for the calculation of the MELD were sometimes incongruent, we only included scores which were officially reported in the respective physicians' letters. As for the Child-Pugh scores, due to these incongruences and because they were reported less frequently, we were not able to assess them for most patients. Thus, we did not include the Child-Pugh score in our study. For the groups who underwent LTX we included the official MELD score reported closest to the date of LTX, while for the PreTx group we used the MELD score closest to the sample collection date.
MOLECULAR ANALYSIS
Leptin plasma expression 
Leptin gene methylation
Methylation of cytosine bases in the context of a consecutive guanosine base is a common means of regulating gene expression in mammals. In this study, methylation was assessed as percentage of C/T after bisulfite conversion and sequencing, C representing methylated cytosines and T representing converted unmethylated cytosines. The following preparation steps for the analysis of CpG methylation were the same for all blood samples (PBMCs). It has been previously described in other methylation analysis studies conducted by our research group (see for example, Glahn et al., 2017; Heberlein et al., 2017) and is a standard procedure frequently used in our laboratory. The extraction from blood and cleanup of genomic deoxyribonucleic acid (DNA) was performed using the NucleoMag ® Blood 200 μL DNA Kit (Macherey-Nagel, Dueren, Germany). Modification of the genomic DNA was done with sodium bisulfite to deaminate unmethylated cytosines to uracils using the Epitect Bisulfite Kit (QIAGEN, Hilden, Germany). The primers used were specifically designed to amplify CpG sites within the promoter regions of leptin. For amplification of the products we performed a (semi-)nested touch-down polymerase chain reaction (PCR). After purification of the PCR product using AmPure (Beckman Coulter, Brea, USA) each product was visualized on a standard 2.0% agarose gel. The purification of the sequencing PCR was performed with CleanSeq (Beckman Coulter, Brea, USA). Sequencing in reverse direction was conducted with a maximum of 30 ng of purified PCR product using a BigDye_Terminator v3.1 Cycle Sequencing Kit (ABI Life Technologies, Grand Island, USA) and the 3500xl Genetic Analyzer (ABI Life Technologies, Grand Island, USA) according to the manufacturer's instructions. Finally, leptin levels were assessed using the DuoSet enzyme-linked immunosorbent assay (ELISA) Development System (Uscn Life Science Inc. Wuhan).
STATISTICS
Leptin plasma expression
We used the Statistics Package for the Social Sciences 24 (IBM, Armonk, USA) and Microsoft Excel 16 (Microsoft, Redmond, USA) for our data collection and analysis of variance and to assess the presence of normality. Before choosing a test for our analysis, we tested for normality and homoscedasticity of variances in each sample group. To do so, we used Kolmogorov-Smirnov test to assess the presence of normality and Levene's test for variance homogeneity. In case of Leptin levels, we used log10 transformation to attain normality before comparing groups via ANOVA, using two-tailed post-hoc correction according to Tukey's method. The logarithmic leptin expression values were normally distributed according to both Kolmogorov-Smirnov test and Shapiro-Wilk test (KolmogorovSmirnov: P = 0.200, Shapiro-Wilk: P = 0.062).
Leptin gene methylation
According to both Kolmogorov-Smirnov and Shapiro-Wilk tests, methylation data (mean methylation) were normally distributed, and therefore we chose to use parametric tests for further analysis (Kolmogorov-Smirnov: P = 0.053, Shapiro-Wilk: P = 0.745). Similar to the plasma expression, the significance level was set at α = 0.05.
We compared the mean methylation for all CpGs of our sample groups by controlling for multiple testing via the Bonferroni and Tukey tests. We then decided to do all further calculations for all CpGs.
We fitted a mixed linear model (MLM) in which methylation was considered as the dependent variable, while leptin expression, group and CpG were implemented as factors. In this model, CpG codes for the respective position in the promoter. Here we calculated a pairwise comparison between groups in which the α-level was set at 0.05. For the graphical presentation of our data, we used the estimated marginal means (EMMs) which were calculated in our model.
RESULTS
Leptin protein measurements
The range of the average leptin values was 7.57-38.25, the lowest being found in the AD group, the highest in Pre-Tx (see Fig. 1a ). The logarithmic (basis 10) leptin expression was significantly higher in C when compared to AD (mean difference (MD) = 0.38892, P < 0.05) and also lower in AD when compared to Pre-Tx (MD = −0.57157, P < 0.001). C-Tx leptin expression was significantly lower when compared to Pre-Tx (MD = −0.49320, P = 0.001). It was also significantly lower Pre-Tx when compared to Post-Tx (MD = 0.51766, P < 0.001) (Table S1 ).
Leptin promoter methylation
Visual inspection of methylation rates across the 63 CpG islands of the promoter indicated a general difference in methylation patterns. When comparing mean methylation levels between groups using the Tukey method, only one significant difference was found, namely between AD patients and C-Tx (MD = 0.09872, P = 0.033).
Association of leptin promoter methylation with leptin protein levels
To analyze the methylation patterns, we calculated the MLM for pairwise comparisons between groups. Here we found the following significant differences (see Fig. 1b ): C vs. AD (MD = −0.063, P = 0.000), C vs. C-Tx (MD = 0.054, P = 0.000), C vs. Post-Tx (MD = 0.027, P = 0.022), AD vs. C-Tx (MD = 0.117, P = 0.000), AD vs. Pre-Tx (MD = 0.081, P = 0.000), AD vs. Post-Tx (MD = 0.090, P = 0.000) and C-Tx vs. Pre-Tx (MD = −0.036, P = 0.008). It is worth mentioning that no significant differences were found between C-Tx vs. Post-Tx (MD = −0.027, P = 0.081) and Pre-Tx and Post-Tx (MD = 0.009, P = 0.452).
To control for age-related methylation changes, we calculated the spearman's rank order correlation of age (at the timepoint where the sample was drawn) with the mean methylation (P = 0.74, correlation coefficient = 0.163, see Table S2 ).
DISCUSSION
To the best of our knowledge, this is the first study that investigates leptin expression and promoter methylation in the context of LTX and end-stage ELC. We have shown that leptin had its highest levels Pre-Tx and decreased after LTX to levels comparable to those found in the AD group. Thereby our study outlines the potential role of leptin protein levels as a marker for AD-related liver damage, contrasting it from AD without induction of such liver damage.
Since we did not include non-AD patients with LC before LTX in our study, we cannot draw any conclusion on a possible difference between them and ELC patients. Nevertheless, because mean methylation was not significantly different between the Pre-Tx and Post-Tx groups but only significantly higher Pre-Tx when compared to C-Tx, we consider this difference in leptin regulation to suggest that regulatory mechanisms could depend on the etiology of the cirrhosis and the respective pathophysiological changes. However, it is important to stress that in this setting we cannot draw any conclusions about a causal relationship between LTX and a change in leptin expression and promoter methylation. Nevertheless, as leptin expression was significantly higher Pre-Tx when compared to Post-Txwhile the mean methylation was not significantly different-it is possible that the cirrhotic patient's leptin is regulated via other mechanisms than promoter methylation. Keeping in mind the difference in promoter methylation between C-Tx and Pre-Tx (C-Tx having significantly lower values when compared with Pre-Tx), one could argue that-because Pre-Tx showed both different leptin and promoter methylation values when compared with C-Tx but only higher leptin expression when compared with Post-Tx-leptin expression is regulated differently in ELC when compared to other forms of LC. If one assumes a substantial regulation via epigenetic means, one could argue that if there is a significant difference in leptin expression levels then this would also translate into a significant difference in promoter methylation levels. However, only for the C-Tx group we were able to show a significant difference when compared with Pre-Tx for both leptin expression and promoter methylation. Hence the combined expression and methylation values show a different pattern in the C-Tx group as opposed to the Post-Tx group when compared with Pre-Tx. This further strengthens the argument that leptin could be regulated differently in end-stage ELC.
Being a pilot study, we looked at a small and-due to our constraints-highly diverse sample. Despite resulting incongruences, it is more intriguing to see these diverse patients show limited variance in protein and methylation measurements, thereby indicating a robust phenomenon that could be extrapolated to larger cohorts. Based on the literature, we had expected that leptin expression would be higher in the AD group when compared to C, which was not the case. This can be explained by two factors: leptin expression is higher in women when compared to men (Hickey et al., 1996) and is associated with body fat (Friedman, 2002; Al Maskari and Alnaqdy, 2006) . Among controls, the sex-ratio was 1:1, while in the AD group it was 3:1 (males:females). When comparing the leptin values between the 12 male and 12 female controls, average leptin was 34.49 for females and 8.93 for males. The higher values can therefore be explained by the number of women. To this end, one could propose using an index of leptin levels per BMI, but this would be inappropriate in this setting: BMI takes only into account weight and height, disregarding the relation between muscular and fat tissue. Cirrhotic patients cannot be compared to healthy controls via the BMI because of possible ascites or nutritional catabolism due to inhibited liver function.
There are several limitations regarding the scope of this study. First, we were not able to measure craving in our cohort due to the retrospective character of this study. In Germany, AD patients have to remain abstinent for 6 months prior LTX and it could be argued that the leptin levels found in our Pre-Tx group do not represent craving, as it can change over the period of abstinence and present itself through an 'incubation of craving' phenomenon (Li et al., 2015) . Because we were not able to measure craving in our cirrhotic samples, we cannot draw any conclusions on a possible relationship between craving and leptin values for this sample. Nevertheless, from a physiological perspective, the high leptin expression found Pre-Tx can potentially be explained by the damage done to the liver. In this model, methylation was used as the dependent variable, leptin expression, CpG and group as the factors. Significant effects are indicated by asterisks (*P ≤ 0.05, **P ≤ 0.01 and ***P < 0.001) C = controls; AD = alcohol-dependent patients; C-Tx = cirrhosis patients without ethyltoxic cirrhosis after LTX; Pre-Tx = ethyltoxic cirrhosis patients before LTX; Post-Tx = ELC patients after LTX. Each bar represents mean ± SEM.
Future studies need to differentiate between the levels of leptin expression and promoter methylation which can be explained by craving and those that relate to the consequences of fibrotic processes. This is the case because leptin expression relates to craving in a way currently not fully understood while it is also upregulated in cirrhosis (see Introduction section). Because promoter methylation is one regulatory mean of leptin expression, we think it is important to analyze the relationship between leptin expression and craving together with pathological markers and diagnostic tools that assess liver steatosis, fibrosis and cirrhosis. In addition, due to the drastically different variance in age across groups as well as its nonparametric distribution over the whole cohort, we did not include age as a covariate for modeling the group differences. It is important to note this confounding factor, as age is known to be a natural modulator of methylation. Nevertheless correlation of the global means data did not correlate with age, indicating an independent influence (Table S2 ). While descriptive display of leptin plasma levels for the sexes is possible, differences could not be validated, as the disparity between sexes did not allow for statistical testing.
We have presented a small and heterogeneous sample, limiting conclusions that could be drawn from our data. For future studies, samples could be gathered immediately before alcohol withdrawal and at specific intervals before and after LTX, while simultaneously assessing craving with the reliable and valid obsessive-compulsive drinking scale (Anton, 2000) . In nicotine, addiction factors such as sex (Lemieux et al., 2015) have been associated with leptin and craving and leptin has been previously regarded as a craving marker in smoking (Potretzke et al., 2014) . Nicotine addiction could be discussed as a possible covariate since smoking is often associated with alcohol dependence (Zullino et al., 2000) .
CONCLUSION
In this study, we discovered that ELC patients have higher leptin values Pre-Tx when compared to ELC patients Post-Tx. Leptin promoter methylation is significantly higher Pre-Tx compared to C-Tx. This could imply other regulatory mechanisms of leptin in those patients who suffer from ELC. Therefore leptin could be regulated differently in regards to underlying etiologies of the LC. Nevertheless, we can currently only describe the relationship between LTX and leptin expression and its promoter methylation without drawing further conclusions on causal relationships. Our data suggest that leptin regulation is altered in ethyltoxic liver disease when compared to LC caused by other pathologies. Future studies may focus on the neurobiology of craving mediated by the hormone leptin in patients with ethyltoxic cirrhosis.
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